Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study

Fig. 5

Response to pembrolizumab in a case with KIF5B-RET fusion and a high level of PD-L1 expression. a Adenocarcinoma nature (10×). b High level of PD-L1 expression (TPS = 50%). c Computed tomography scan and magnetic resonance imaging revealing the clinical response to pembrolizumab. Abbreviations: PD - progression disease

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us